CINXE.COM

<!doctype html> <html lang="en"> <head> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <title>Veto-Engineering Immune Tolerance</title> <meta name="keywords" content="Immune system; CAR-T cell therapy; hematopoietic stem cell transplantations"> <meta name="description" content="The old veto effect may be moving from its status as an obscure immune inhibitory phenomenon to an important role on specific immune suppression. In today&.. "/> <meta name="citation_publisher" content="Longdom Publishing S.L"/> <meta name="citation_journal_title" content="Journal of Hematology & Thromboembolic Diseases"> <meta name="citation_title" content="Veto-Engineering Immune Tolerance"> <meta name="citation_author" content="Uwe D Staerz"/> <meta name="citation_author" content="Janae W Cull"/> <meta name="citation_author" content="Yan Qi"/> <meta name="citation_year" content="2024"> <meta name="citation_volume" content="12"> <meta name="citation_issue" content="6"> <meta name="citation_doi" content="10.35248/2329-8790.24.12.609"> <meta name="citation_issn" content="2329-8790"> <meta name="citation_publication_date" content="2024/07/15"/> <meta name="citation_firstpage" content="1"> <meta name="citation_lastpage" content="4"> <meta name="citation_abstract" content="The old veto effect may be moving from its status as an obscure immune inhibitory phenomenon to an important role on specific immune suppression. In today's clinical practice, broad suppression of the immune system is employed to avoid transplant rejection and mitigate auto-aggressive immune responses. Though highly effective, this approach impairs immune protection against infectious challenges. Therapeutic approaches are being sought that specifically inhibit sections of the immune system without affecting beneficial immune functions. One such tactic entails the classical veto-effect that employs donor-derived CD8+ T cells to inhibit cellular immune responses. Indeed, this kind of veto has already found applications as the underpinning of a more broadly applicable CAR-T cell therapy and of a more spec0069fic immune suppression for haploidentical Hematopoietic Stem Cell (HSC) transplantations. To broaden and simplify the use of veto, engineering strategies are discussed that affix its immune inhibitory function to cells of different tissues. They are based on the transfer of the CD8 α-chain to the surface of different cell populations. We predict that engineered veto will simplify specific immune suppression and broadening its application to organ transplantations and possibly the treatment of autoimmune diseases. It may represent an avenue to induce immunological tolerance."> <meta name="citation_fulltext_html_url" content="https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html"> <meta name="citation_pdf_url" content="https://www.longdom.org/open-access/vetoengineering-immune-tolerance.pdf"> <meta name="citation_abstract_html_url" content="https://www.longdom.org/abstract/vetoengineering-immune-tolerance-109360.html"> <meta name="format-detection" content="telephone=no" /> <meta name="google-site-verification" content="NomPTP94YozsgvD3NEFpNqUfY88e0TU0L64zNzZTpd0" /> <meta itemprop="name" content="longdom" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="ROBOTS" content="INDEX,FOLLOW" /> <meta name="googlebot" content="INDEX,FOLLOW" /> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no" /> <link rel="canonical" href="https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" /> <link rel="alternate" href="https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" hreflang="en-us" /> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "Organization", "url": "https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html", "logo": "https://www.longdom.org/assets/img/longdom-logo.svg" } </script>  <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" /> <link href="/assets/css/longdom.css" rel="stylesheet" /> <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.7.0/animate.min.css" />  <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.7.1/css/all.css" /> <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" />   <link href="/assets/css/ionicons.min.css" rel="stylesheet" />  <link rel="stylesheet" href="/assets/css/jquery.mCustomScrollbar.min.css" /> <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-select/1.13.2/css/bootstrap-select.min.css" />  <link rel="stylesheet" href="/assets/css/global.css" />  <link rel="stylesheet" href="/assets/css/styles.css" /> <link rel="stylesheet" type="text/css" href="/assets/css/author.css" /> <link rel="icon" href="/assets/img/favicon.png" type="image/gif" /> <link rel="stylesheet" href="/assets/css/coolautosuggest.css" />   <script async src="https://www.googletagmanager.com/gtag/js?id=G-LE7WH45F9C"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-LE7WH45F9C'); </script> <meta property="og:title" content="Longdom Publishing SL | Open Access Journals" /> <meta property="og:site_name" content="Longdom" /> <meta property="og:url" content="https://www.longdom.org/" /> <meta property="og:description" content="Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects" /> <meta property="og:type" content="article" /> <meta property="og:image" content="https://www.longdom.org/assets/img/longdom-logo.svg" /> <meta name="twitter:card" content="summary" /> <meta name="twitter:site" content="@org_longdom" /> <meta name="twitter:title" content="Longdom Publishing SL | Open Access Journals" /> <meta name="twitter:description" content="Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects." /> <meta name="twitter:image" content="https://www.longdom.org/assets/img/longdom-logo.svg" />  <script> !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','//connect.facebook.net/en_US/fbevents.js'); fbq('init', '297919997051754'); fbq('track', "PageView"); </script>  <script type="text/javascript"> function openimage( theURL, winName, features ) { window.open( theURL, winName, features ); } </script> </head> <body> <header>  <nav class="navbar navbar-expand-lg navbar-light bg-white shadow-sm deva541"> <div class="container"> <a class="navbar-brand" href="https://www.longdom.org/" title="Longdom Publishing S.L"> <img src="/assets/img/longdom-logo.svg" alt="" height="25"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar"> <div class="navbar-nav"> <a class="nav-item nav-link" href="https://www.longdom.org/" title="Home">Home</a> <div class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="Guidelines" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Journals</a> <div class="dropdown-menu" aria-labelledby="Journals"> <a class="dropdown-item" href="https://www.longdom.org/journals-by-title.html" title="A-Z Journals">A-Z Journals</a> <a class="dropdown-item" href="https://www.longdom.org/open-access-journals-list.html" title="Browse By Subject">Browse By Subject</a> </div> </div> <div class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="Guidelines" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Guidelines & Policies </a> <div class="dropdown-menu" aria-labelledby="Guidelines"> <a class="dropdown-item" href="https://www.longdom.org/editorial-policies.html" title="Editorial Policies">Editorial Policies</a> <a class="dropdown-item" href="https://www.longdom.org/submit-manuscript.html" title="Online Submission">Online Submission</a> <a class="dropdown-item" href="https://www.longdom.org/instructions-to-authors.html" title="Instructions to Authors">Instructions to Authors</a> <a class="dropdown-item" href="https://www.longdom.org/policies.html" title="Policies">Policies</a> <a class="dropdown-item" href="https://www.longdom.org/publication-ethics.html" title="Publication ethics & malpractice statement">Publication ethics & malpractice statement</a> <a class="dropdown-item" href="https://www.longdom.org/reviewers.html" title="Reviewers">Reviewers</a> <a class="dropdown-item" href="https://www.longdom.org/terms-conditions.html" title="Terms and Conditions">Terms and Conditions</a> </div> </div> <a class="nav-item nav-link" href="https://www.longdom.org/advertising.html" title="Advertising">Advertising</a> <a class="nav-item nav-link" href="https://www.longdom.org/conferences.html" title="Conferences">Conferences</a> <a class="nav-item nav-link" href="https://www.longdom.org/contact-us.html" title="Contact us">Contact us</a> <div id="google_translate_element"></div> </div>  </div> </div> </nav> </header>  <section class="bg-info py-1"> <div class="container"> <div class="row align-items-center justify-content-between">  <div class="col-12 col-sm-auto"> <img src="https://www.longdom.org/admin/headers/journal-of-hematology--thromboembolic-diseases-logo.svg" alt="Journal of Hematology & Thromboembolic Diseases" width="105" height="105" class="img-fluid mx-auto"> </div> <div class="col-12 col-sm-8"> <h1 class="text-left text-white border-light-blue-200-before font-size-7">Journal of Hematology & Thromboembolic Diseases<br><small class="float-right font-size-5">Open Access</small></h1> </div>  <div class="col-12 col-sm-2 d-none d-sm-block"> <p class="lead">ISSN: 2329-8790</p>  <div id="feedback" class="card card-body p-1 font-size-2 shadow-sm z-index-1"> <div class="reach-us-animated"></div> <p class="card-text"><img src="/assets/img/whatsapp.svg" alt="" width="20" class="ml-2"> +44 1478 350008</p> </div> </div> </div> </div> </section>  <nav id="sticky-navbar" class="navbar navbar-expand-lg navbar-dark bg-primary py-0"> <div class="container"> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#jrnlNavbar" aria-controls="jrnlNavbar" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-center" id="jrnlNavbar"> <div class="navbar-nav"> <a class="nav-item nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases.html" title="Journal Home">Journal Home</a> <div class="nav-item dropdown"> <a class="nav-link dropdown-toggle " href="#" id="EditorialPanel" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Editorial Panel <i class="fas fa-caret-down"></i></a> <div class="dropdown-menu" aria-labelledby="EditorialPanel"> <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/editor-in-chief.html" title="Editor-in-Chief">Editor-in-Chief</a> <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/editorial-board.html" title="Editorial Board">Editorial Board</a> </div> </div> <div class="nav-item dropdown"> <a class="nav-link dropdown-toggle " title="Instructions for Authors" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" href="#">Instructions for Authors <i class="fas fa-caret-down"></i></a> <div class="dropdown-menu" aria-labelledby="EditorialPanel"> <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/instructionsforauthors.html" title="Instructions for Authors">Instructions for Authors</a>  <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/ethical-malpractices.html" title="Publication ethics & malpractice statement">Publication ethics & malpractice statement</a> </div> </div> <a class="nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases/submit-manuscript.html" title="Submit Manuscript">Submit Manuscript</a> <a class="nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases/aim-and-scope.html" title="Aims and Scope">Aims and Scope</a> <a class="nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases/inpress.html" title="Articles in process">Articles in process</a>  <a class="nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases/archive.html" title="Archive">Archive</a> <div class="nav-item dropdown"> <a class="nav-link dropdown-toggle " href="#" id="SpecialIssues" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Special Issues <i class="fas fa-caret-down"></i></a> <div class="dropdown-menu" aria-labelledby="SpecialIssues"> <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/guidelines.html" title="Guidelines">Guidelines</a> <a class="dropdown-item" href="https://www.longdom.org/haematology-thromboembolic-diseases/upcoming-special-issues.html" title="Upcoming Special Issues">Upcoming Special Issues</a> </div> </div> <a class="nav-item nav-link " href="https://www.longdom.org/haematology-thromboembolic-diseases/contact.html" title="Contact">Contact</a> </div> </div> </div> </nav> <script type="text/javascript"> function googleTranslateElementInit() { new google.translate.TranslateElement({pageLanguage: 'en'}, 'google_translate_element'); } </script> <script type="text/javascript" src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script> <section class="py-4 content"> <div class="container"> <div class="row"> <aside class="col-12 col-sm-3 order-last order-sm-first"> <a href="https://www.longdom.org/haematology-thromboembolic-diseases/awards-nomination.html" class="btn btn-info btn-block mb-3 border-0 border-left-4 border-info font-size-4"><i class="fa-light fa-award-simple"></i> Awards Nomination </a> <a href="https://www.longdom.org/haematology-thromboembolic-diseases-online-visitors-readers-190.html" class="btn btn-warning btn-block mb-3 border-0 border-left-4 border-info font-size-4"><i class="fas fa-book-reader"></i> 25+ Million Readerbase</a>  <div class="card shadow-sm sidebar mb-3"> <div class="list-group list-group-flush qr_code_image"> <img title="QR" src="https://chart.googleapis.com/chart?chs=185x185&cht=qr&chl=https%3A%2F%2Fwww.longdom.org%2Fopen-access%2Fvetoengineering-immune-tolerance-109360.html&chld=M|0&icqrf=00b1e4" alt="Longdom"/>  <nav class="nav nav-pills social-icons-footer sidebar_social_icons a-pl-0"> <a title="Share This Article" target="_blank" class="nav-link" rel="noopener" href="https://www.facebook.com/sharer.php?s=100&p[title]=Veto-Engineering Immune Tolerance&p[url]=https%3A%2F%2Fwww.longdom.org%2Fopen-access%2Fvetoengineering-immune-tolerance-109360.html"><img src="https://www.longdom.org/assets/socials/facebook.png" alt="Longdom" /></a> <a title="Share This Article" target="_blank" class="nav-link" rel="noopener" href="https://web.whatsapp.com/send?text=https%3A%2F%2Fwww.longdom.org%2Fopen-access%2Fvetoengineering-immune-tolerance-109360.html" title="Share This Article" target="_blank" class="nav-link"><img src="https://www.longdom.org/assets/socials/whatsapp.png" alt="Longdom"/></a> <a title="Share This Article" target="_blank" class="nav-link" rel="noopener" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.longdom.org%2Fopen-access%2Fvetoengineering-immune-tolerance-109360.html" title="Share This Article" target="_blank" class="nav-link"><img src="https://www.longdom.org/assets/socials/linkedin.png" alt="Longdom"/></a> <a title="Share This Article" target="_blank" class="nav-link" rel="noopener" href="https://twitter.com/share?text=Veto-Engineering Immune Tolerance&url=https%3A%2F%2Fwww.longdom.org%2Fopen-access%2Fvetoengineering-immune-tolerance-109360.html" class="nav-link"><img src="https://www.longdom.org/assets/socials/twitter.png" alt="Longdom" /></a> </nav>  </div> </div>     <h6><a target="_blank" href="https://scholar.google.com/citations?user=fnhxWFsAAAAJ&hl=enhxWFsAAAAJ&hl=en" title="Click here">Google Scholar citation report</a></h6> <h6 style="font-weight:bold;">Citations : 1065</h6> <p><a target="_blank" href="https://scholar.google.com/citations?user=fnhxWFsAAAAJ&hl=enhxWFsAAAAJ&hl=en" title="Click here">Journal of Hematology & Thromboembolic Diseases received 1065 citations as per Google Scholar report</a></p> <div class="card shadow-sm sidebar mb-3"> <a href="https://www.longdom.org/haematology-thromboembolic-diseases/citations.html" title="Click here"><img src="https://www.longdom.org/admin/citation-images/journal-of-hematology--thromboembolic-diseases-citation.PNG" alt="Citation" class="img-fluid p_rel" /></a> </div>   <div class="card shadow-sm sidebar mb-3"> <h6 class="card-header pr-0">Indexed In</h6> <div class="list-group list-group-flush overflow-view"> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Open J Gate </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Academic Keys </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> RefSeek </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Hamdard University </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> EBSCO A-Z </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> OCLC- WorldCat </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Publons </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Geneva Foundation for Medical Education and Research </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Euro Pub </div> <div class="list-group-item p-0 pt-2 pl-2"> <i class="fa fa-chevron-right" style="font-size: 11px;color: #0056b3;"></i> Google Scholar </div> </div> <p class="m-0 clearfix"><a href="https://www.longdom.org/haematology-thromboembolic-diseases/indexing.html" title="Click here"><span class="btn btn-warning btn-xs float-right">View More »</span></a></p> </div>   <div class="card shadow-sm sidebar mb-3"> <h6 class="card-header">Useful Links</h6> <div class="card-body p-0"> <nav class="nav flex-column font-size-3 icon-list icon-list-angle-right a-py-1"> <a class="nav-item nav-link" href="https://www.longdom.org/covid-19-peer-reviewed-journals-articles-special-issues.html" title="Click Here">Covid-19 Journal Articles Issues</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/aim-and-scope.html" title="Click Here">Aim and Scope</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/peer-review-process.html" title="Click Here">Peer Review Process</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/other-comments.html" title="Click Here">Other Comments</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/advertising.html" title="Click Here">Advertising</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/citations.html" title="Click Here">Citations Report</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/indexing.html" title="Click Here">Indexing and Archiving</a> <a class="nav-item nav-link" href="https://www.longdom.org/haematology-thromboembolic-diseases/archive.html" title="Click Here">Table of Contents</a> <a class="nav-item nav-link" href="https://www.longdom.org/submissions/hematology-thromboembolic-diseases.html" title="Click Here">Submit Paper</a> <a class="nav-item nav-link" href="https://www.longdom.org/editorial-tracking/" title="Click Here">Track Your Paper</a> <a class="nav-item nav-link" href="https://www.longdom.org/funded-articles.html" title="Click Here">Funded Work</a> </nav> </div> </div>  <div class="card shadow-sm sidebar mb-3" style="margin-top:10px"> <h6 class="card-header">Share This Page</h6> <div class="card-body"> <nav class="nav social-icons social-icons-sm"> <a class="nav-link bg-facebook white" href="https://www.facebook.com/sharer.php?u=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" target="_blank" title="Share with Facebook" rel="noopener"><i class="fab fa-facebook-f"></i></a> <a class="nav-link bg-twitter white" href="https://twitter.com/share?url=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" rel="noopener" target="_blank" title="Share with Twitter"><i class="fab fa-twitter"></i></a> <a class="nav-link bg-linkedin white" href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" rel="noopener" target="_blank" title="Share with Linkdin"><i class="fab fa-linkedin-in"></i></a> <a class="nav-link bg-googleplus white" href="https://plus.google.com/share?url=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" target="_blank" rel="noopener" title="Share with Google+"><i class="fab fa-google-plus-g"></i></a> <a class="nav-link bg-pinterest white" href="https://pinterest.com/pin/create/button/?url=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" rel="noopener" target="_blank" title="Share with Pintrest"><i class="fab fa-pinterest-p"></i></a> <a class="nav-link bg-blogger white" href="https://www.blogger.com/blog-this.g?u=https://www.longdom.org/open-access/vetoengineering-immune-tolerance-109360.html" rel="noopener" target="_blank" title="Share with Blogger"><i class="fab fa-blogger-b"></i></a> </nav> </div> </div>  <div class="card shadow-sm sidebar mb-3"> <h6 class="card-header">Recommended Journals</h6> <div class="card-body p-0"> <nav class="nav flex-column font-size-3 icon-list icon-list-angle-right a-py-1"> <a class="nav-item nav-link" href="https://www.longdom.org/cell-developmental-biology.html" title="Click Here">cell biology</a> <a class="nav-item nav-link" href="https://www.longdom.org/lupus.html" title="Click Here">lupus</a> <a class="nav-item nav-link" href="https://www.longdom.org/leukemia.html" title="Click Here">Leukemia journal</a> </nav> </div> </div>  <div class="card shadow-sm sidebar mb-3"> <a href="https://www.longdom.org/haematology-thromboembolic-diseases/advertising.html" title="Click here"><img src="https://www.longdom.org/assets/img/tower-banner.jpg" alt="Flyer image" class="img-fluid p_rel" /> <span class="p_abo cu_roundchip"> <span> <h5><span>25+</span> Million Website Visitors</h5> </span> </span> </a> </div>    <div class="card shadow-sm sidebar mb-3"> <h6 class="card-header">Journal Flyer</h6> <img src="https://www.longdom.org/admin/flyers/Journal-of-Hematology--Thromboembolic-Diseases-flyer.jpg" alt="Journal of Hematology & Thromboembolic Diseases" class="img-fluid"/> </div>   <div class="sidebar pt-20 pl-10 mt-xs-0" align="center"> <a class="twitter-timeline" href="https://twitter.com/Hematology123" data-width="450" data-height="300">Tweets by Hematology123</a> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script> </div> <div class="clear"> </div>   <div class="card shadow-sm sidebar mb-3"> <h6 class="card-header">Open Access Journals</h6> <div class="card-body p-0 scroll_mang"> <nav class="nav flex-column font-size-3 icon-list icon-list-angle-right a-py-1"> <a class="nav-item nav-link" href="https://www.longdom.org/agri-and-aquaculture-journals.html" title="Click Here">Agri and Aquaculture</a> <a class="nav-item nav-link" href="https://www.longdom.org/biochemistry-journals.html" title="Click Here">Biochemistry</a> <a class="nav-item nav-link" href="https://www.longdom.org/bioinformatics-and-systems-biology-journals.html" title="Click Here">Bioinformatics & Systems Biology</a> <a class="nav-item nav-link" href="https://www.longdom.org/business-and-management-journals.html" title="Click Here">Business & Management</a> <a class="nav-item nav-link" href="https://www.longdom.org/chemistry-journals.html" title="Click Here">Chemistry</a> <a class="nav-item nav-link" href="https://www.longdom.org/clinical-sciences-journals.html" title="Click Here">Clinical Sciences</a> <a class="nav-item nav-link" href="https://www.longdom.org/engineering-journals.html" title="Click Here">Engineering</a> <a class="nav-item nav-link" href="https://www.longdom.org/food-and-nutrition-journals.html" title="Click Here">Food & Nutrition</a> <a class="nav-item nav-link" href="https://www.longdom.org/general-science-journals.html" title="Click Here">General Science</a> <a class="nav-item nav-link" href="https://www.longdom.org/genetics-and-molecular-biology-journals.html" title="Click Here">Genetics & Molecular Biology</a> <a class="nav-item nav-link" href="https://www.longdom.org/immunology-and-microbiology-journals.html" title="Click Here">Immunology & Microbiology</a> <a class="nav-item nav-link" href="https://www.longdom.org/medical-sciences-journals.html" title="Click Here">Medical Sciences</a> <a class="nav-item nav-link" href="https://www.longdom.org/neuroscience-and-psychology-journals.html" title="Click Here">Neuroscience & Psychology</a> <a class="nav-item nav-link" href="https://www.longdom.org/nursing-and-health-care-journals.html" title="Click Here">Nursing & Health Care</a> <a class="nav-item nav-link" href="https://www.longdom.org/pharmaceutical-sciences-journals.html" title="Click Here">Pharmaceutical Sciences</a> </nav> </div> </div>  </aside> <div class="col-12 col-sm-9 full-text"> <div class="row align-items-center justify-content-between"> <div class="col-12 col-sm-4"> <p class="text-muted mb-0"> Mini Review - (2024)Volume 12, Issue 6 </p> </div> <div class="col-12 col-sm-8 text-right custom-column"> <a href="https://www.longdom.org/open-access/vetoengineering-immune-tolerance.pdf" title="View PDF" class="btn btn-sm bg-green-600 rounded-50"><i class="fas fa-file-pdf"></i> View PDF</a> <a href="https://www.longdom.org/pdfdownload.php?download=open-access/vetoengineering-immune-tolerance.pdf&aid=109360" title="Download PDF" class="btn btn-sm bg-green-600 rounded-50"><i class="fas fa-download"></i> Download PDF</a> </div> </div> <h2 class="font-size-7 mt-2">Veto-Engineering Immune Tolerance</h2> <a href='https://www.longdom.org/author/janae-w-cull-71344' title='Janae W Cull' style='color:#555; border-bottom:1px dotted #CCC;'>Janae W Cull</a>, <a href='https://www.longdom.org/author/yan-qi-71345' title='Yan Qi' style='color:#555; border-bottom:1px dotted #CCC;'>Yan Qi</a> and <a href='https://www.longdom.org/author/uwe-d-staerz-71346' title='Uwe D Staerz' style='color:#555; border-bottom:1px dotted #CCC;'>Uwe D Staerz</a><sup><a href='#Uwe_D_Staerz'>*</a></sup> <div> </div> <a id="Uwe_D_Staerz"></a> <strong><sup>*</sup>Correspondence:</strong> Uwe D Staerz, Department of Research and Development, Greffex Inc, Colorado, USA, <strong>Email:</strong> <i class='fa fa-envelope' aria-hidden='true' title='ustaerz@greffex.com'></i> <p><a href="#ai"><strong>Author info »</strong></a></p> <div class="card bg-light mb-3"> <div class="card-body px-3 pb-0"> <h2 class="font-size-5">Abstract</h2> <p>The old veto effect may be moving from its status as an obscure immune inhibitory phenomenon to an important role on specific immune suppression. In today's clinical practice, broad suppression of the <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/immune-system-8102.html'>immune system</a> is employed to avoid transplant rejection and mitigate auto-aggressive immune responses. Though highly effective, this approach impairs immune protection against infectious challenges. Therapeutic approaches are being sought that specifically inhibit sections of the <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/immune-system-8102.html'>immune system</a> without affecting beneficial immune functions. One such tactic entails the classical veto-effect that employs donor-derived CD8+ T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> to inhibit cellular immune responses. Indeed, this kind of veto has already found applications as the underpinning of a more broadly applicable CAR-T cell therapy and of a more spec0069fic immune suppression for haploidentical <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/hematopoietic-5255.html'>Hematopoietic</a> <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/stem-cell-49043.html'>Stem Cell</a> (HSC) transplantations. To broaden and simplify the use of veto, engineering strategies are discussed that affix its immune inhibitory function to <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> of different tissues. They are based on the transfer of the CD8 α-chain to the surface of different cell populations. We predict that engineered veto will simplify specific immune suppression and broadening its application to organ transplantations and possibly the treatment of autoimmune diseases. It may represent an avenue to induce immunological tolerance.</p> <h4 class="font-size-4">Keywords</h4> <p>Immune system; CAR-T cell therapy; hematopoietic stem cell transplantations</p> </div> </div> <h4>Introduction</h4> <p>The word veto is derived from the Latin verb vertare and literally translated means I forbid. Veto was first described as an obscure immune inhibitory phenomenon that was induced by the injection of CD8<sup>+</sup> T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> into mice [<a href="#1" title="1">1</a>]. It was subsequently shown that this classical veto removed T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> from the peripheral repertoire in a highly specific and effective manner. T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are guided through their development in the thymus and their fate in the periphery by positive and negative interactions. Immature T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> undergo both expansion and deletion events [<a href="#2" title="2">2</a>]. Bone marrow-derived precursors migrate to the thymus, where T cell differentiation begins with the rearrangement of the T Cell Antigen Receptor (TCR) variable genes. The assembled TCRs are clonally expressed on the surface of thymocytes. During positive selection the immature T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are screened for their ability to recognize antigens in a given Major Histocompatibility Complex (MHC) environment. Only the successful <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are allowed to proceed. Strongly auto-reactive T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are removed in another thymic process. During negative selection, they are either removed from the repertoire or inactivated when they react with self at high affinities. Having completed their development, T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> in the periphery are induced when they exposed to their cognate antigen presented by professional Antigen Presenting <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>Cells</a> (APC). T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are fully activated by the engagement of their TCR in concert with a costimulatory molecule [<a href="#3" title="3">3</a>]. They are inhibited when their specific antigen is not presented on professional APCs. Their activity can also be inhibited by regulatory T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> [<a href="#4" title="4">4</a>]. It is not known whether veto inhibition represents a physiological mechanism to preserve peripheral tolerance.</p> <h4>Literature Review</h4> <p> The mechanistical underpinning of classical veto differs from other peripheral processes. Veto was first seen when animals were injected with lymphocyte populations enriched for Cytotoxic T Lymphocytes (CTL) [<a href="#1" title="1">1</a>]. It was found that CTL precursors that had been exposed to their antigen on CD8<sup>+</sup> T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> were removed from the peripheral T cell repertoire. Veto was shown to inhibit the induction of T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> with specificities for allogeneic MHC, as well as minor and haptenated histocompatibility antigens. In its classical form, the veto-ing T cell is passive. It does not have to recognize the inhibited cell, but rather must be recognized to delete the responsive T cells. Thus, the specificity of the veto-ing CD8<sup>+</sup> T cell is not crucial for this form of specific immune inhibition. Although it was shown that a retrograde killing of the CD8<sup>+</sup> T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> enhanced veto inhibition, it was not mandatory. It was found that also nonlytic CD8<sup>+</sup> Bone-Marrow (BM) <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> elicited veto inhibition [<a href="#5" title="5">5</a>]. Further mechanistical studies demonstrated that a trigger of the veto inhibitory function rested in the CD8 α-chain. Deleting the expression of the CD8 α-chain removed the ability of <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> to veto [<a href="#6" title="6">6</a>,<a href="#7" title="7">7</a>]. <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>Cells</a> gained this function after they had acquired the CD8 α-chain on their surfaces. Having established the central role of the CD8 α-chain, the most straightforward explanation of classical veto employs a co-triggering paradigm (<strong>Figure 1</strong>).</p> <a onclick="openimage('https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-Classical-12-6-609-g001.png','','scrollbars=yes,resizable=yes,width=500,height=330')" class="thumbnail"> <img src="https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-Classical-12-6-609-g001.png" class="img-thumbnail img-fluid d-block mx-auto" alt="Classical" title="Classical" /></a> <p><strong>Figure 1:</strong> Classical veto- T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> that recognize CD8<sup>+</sup> T cells, i.e. classical veto cells, are triggered through their TCRs and their surface MHC class I molecules. As a consequence, the veto-ed T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> will be inactivated or deleted. Triggering of their surface Fas (CD95) enhances the deletion signal. <strong>Note:</strong> <img class="img-responsive" src="https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-12-6-609-e001.png" alt="Equation" /></p> <p>In this model, T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are veto-ed when they receive signals through the TCR complex concurrently with triggers through the α3 domain of their surface MHC class I molecules. Experiments indeed demonstrated that blocking the CD8 binding to the α3 domain of MHC class I molecules on the responding T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> prevented veto inhibition. Receiving a death signal through MHC class I is not implausible. It was found that certain antibodies that bind to the α3 domain of MHC class I molecules induced cell death. This co-triggering theory also explains how both CD4+ and CD8-independent T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are inhibited by classical veto. Besides a silencing of the responding T cells, veto can also result in their deletion. Co-expression of CD95L with the CD8 α-chain strongly enhances veto-like inhibition that can lead to the death of the triggered cell (<strong>Figure 1</strong>)[<a href="#8" title="8">8</a>]. This lethal veto trigger might also be provided by a release of cytotoxic granules. Even though expression of CD95L on some <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/hematopoietic-5255.html'>Hematopoietic</a> Stem <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>Cells</a> (HSC) or on other tissues can lead by itself to the <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/apoptosis-5811.html'>apoptosis</a> of activated T cells, this version of inhibition is distinct from classical veto as it does not depend on the engagement of the TCR and is therefore non-antigen specific.</p> <h4>Discussion</h4> <p>The redirecting of T cell activities has delivered major breakthroughs in the therapy of malignancies. The powers of CD8<sup>+</sup> CTLs in eliminating unwanted <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> were harnessed when the unrestricted recognition of an antibody was attached to TCR complexes. In one system, bispecific antibody constructs were developed, in which one binding site was linked to components of the anti-TCR complex and the other one was directed against a chosen tumor antigen [<a href="#9" title="9">9</a>,<a href="#10" title="10">10</a>]. With this approach, a patient’s own T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> can be swiftly recruited to decimate malignant cells. This approach has been successfully deployed in the clinic to the treatment of certain lymphomas [<a href="#11" title="11">11</a>]. In another system, Chimeric Antigen Receptors (CAR) were assembled that grafted antibody variable regions onto TCR signaling proteins. CAR-engineering of autologous T cells requires an efficient and repeated harvesting of large numbers of cells. This is followed by time-consuming manufacturing processes to transfer the CAR T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> before they can be reinfused to the patient [<a href="#12" title="12">12</a>]. A simplification of this therapy would be achieved if off-the-shelf pre-manufactured CAR T cells could be used. Indeed, classical veto might facilitate the transfer of allogeneic CTLs. Here, CAR-engineered CD8<sup>+</sup> T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> from an unrelated doner would provide the therapeutic moiety. Their intrinsic veto activities would negate the attacks by the recipient’s T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> [<a href="#13" title="13">13</a>]. Clinical trials have demonstrated the feasibility of this idea. Graft-versus-Host Disease (GvHD) phenomena were observed in some patients. They were most likely caused by the presence of the original TCRs on the CAR T cells. Deleting these second specificities should resolve the GvHD effects.</p> <p>The rejection of HSC grafts was another issue that was addressed by classical veto. It was reported that in the animal the rejection of mismatched HSCs was mitigated when donorderived CD8<sup>+</sup> veto <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> were added. These findings were confirmed in clinical trials, in which the addition of donorderived T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> lessened the rejection of the haploidentical HSC grafts [<a href="#14" title="14">14</a>].</p> <p><strong>Engineering veto immune suppression</strong></p> <p>Classical veto depends on the activity of <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> that, under physiological conditions, express the CD8 α-chain. Yet, CD8 is only expressed on few cells, such as on a subgroup of peripheral T cells, on minor populations of the BM, and on some rare dendritic cells. Veto is mediated by TCR recognition in conjunction with triggering through the α 3 domain of the MHC class I molecules. An infusion of CD8-bearing cells, such as CTLs, only inhibits T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> that are responsive to antigens expressed on veto-ing cells. T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> reactive with antigens selectively expressed on non-CD8 bearing tissues syngeneic to the inhibitory <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> remain unscathed. Although the major thrust of transplant rejection is caused by T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> that recognize foreign MHC molecules, T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> that specifically recognize tissue-antigens presented on allogenic MHC molecules participate in graft rejection. The situation is different for autoimmune phenomena. Here, tissue-specific T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> are the principal drivers of the diseases. To use veto to limit auto-aggression and to mitigate transplant rejection, its immune suppression must be expanded to tissue-specific T cells. Two engineering technologies were investigated by us to link veto to different tissues (<strong>Figure 2</strong>).</p> <a onclick="openimage('https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-Engineered-12-6-609-g002.png','','scrollbars=yes,resizable=yes,width=500,height=330')" class="thumbnail"> <img src="https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-Engineered-12-6-609-g002.png" class="img-thumbnail img-fluid d-block mx-auto" alt="Engineered" title="Engineered" /></a> <p><strong>Figure 2:</strong> Engineered veto-Cells are engineered to become veto <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> by their transduction with a vector that carries a CD8 α- chain transgene expression cassette or by a hybrid antibody that attaches a CD8 α-chain onto their surface. The veto-ed T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> will be inactivated or deleted. An extended maintenance of engineered veto <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> in animals also induces inhibitory immune regulatory cells. <strong>Note: </strong><img class="img-responsive" src="https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-12-6-609-e002.png" alt="Equation" /><img class="img-responsive" src="https://www.longdom.org/articles-images-2024/Hematology-Thromboembolic-12-6-609-e003.png" alt="Equation" /></p> <p>We constructed Hybrid Antibodies (HAb) that linked an antibody variable region specific for an MHC class I molecule to the CD8 α-chain [<a href="#15" title="15">15</a>,<a href="#16" title="16">16</a>]. We were able to demonstrate that these HAbs effectively transferred veto inhibition to different cell populations. Once the feasibility of veto engineering had been established, we decided to rigorously probe its effectiveness <em>in vivo</em>. HAbs are not maintained long-term on cells. Nevertheless, their surface half-lives might suffice to resolve an autoimmune attack. As the <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/immune-system-8102.html'>immune system</a> takes several days to fully activate allo-reactive T cells, it is unlikely that HAbs can effectively evade <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> rejection. Having investigated different gene transfer systems, we settled on Adenoviral (Ad) vectors that efficiently transduced both proliferating and resting <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> of most phenotypes and had the ability to promptly induce transgene expression. In contrast to retroviral and adeno-associated virus DNA, Ad genomes rarely integrate into the host genome. Yet, as they are maintained as episomes, they are nevertheless preserved in <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> for extended periods of time. We constructed Ad vectors that carried either the mouse or human CD8 α-Chain as Transgenes (AdCD8) [<a href="#17" title="17">17</a>]. Once we had established <em>in vitro</em> that different <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> transduced with either vector specifically inhibited the induction of allogeneic CTLs, we moved to a mouse <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> model. We were able to demonstrate that AdCD8 transduced <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/pancreatic-islets-4337.html'>pancreatic islets</a> were permanently (i.e. lifelong) protected from rejection in fully allogeneic hosts (<strong>Table 1</strong>).</p> <div class="table-responsive"> <table class="table table-striped"> <thead> <tr> <th rowspan="3">Groups</th> <th rowspan="3">Set-up</th> <th rowspan="3">Donor</th> <th rowspan="3">Recipient</th> <th colspan="3">Pancreatic islets</th> <th>Graft survival</th> </tr> <tr> <th colspan="2">Number</th> <th rowspan="2">Islet treatment</th> <th rowspan="2">[%]</th> </tr> <tr> <th>Average</th> <th>SD</th> </tr> </thead> <tbody> <tr> <td>Control#1 </td> <td>Syngeneic </td> <td>C57Bl/6 </td> <td>C57Bl/6 </td> <td>789 </td> <td>231 </td> <td>none </td> <td>100 </td> </tr> <tr> <td rowspan="2">Control#2 </td> <td rowspan="2">Allogeneic </td> <td rowspan="2">C57Bl/6 </td> <td rowspan="2">Balb/c </td> <td>788 </td> <td>104 </td> <td>none </td> <td>0 </td> </tr> <tr> <td>450 </td> <td>10 </td> <td>none </td> <td>0 </td> </tr> <tr> <td>Control#3 </td> <td>Allogeneic </td> <td>C57Bl/6 </td> <td>Balb/c </td> <td>838 </td> <td>46 </td> <td>Ad(empty) </td> <td>0 </td> </tr> <tr> <td>Veto#1 </td> <td>Allogeneic </td> <td>C57Bl/6 </td> <td>Balb/c </td> <td>791 </td> <td>85 </td> <td>AdCD8 </td> <td>83 </td> </tr> <tr> <td>Veto#2 </td> <td>Allogeneic </td> <td>C57Bl/6 </td> <td>Balb/c </td> <td>450 </td> <td>10 </td> <td>AdCD8 </td> <td>91 </td> </tr> </tbody> </table> </div> <p><strong>Table 1:</strong> Pancreatic islet <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> (pancreatic islets harvested from C57Bl/6 mice were treated as listed in the Table. They were transplanted under the kidney capsule of Balb/c mice suffering from chemically induced diabetes mellitus).</p> <p>No supportive immune suppression was required. Having induced tissue-specific immune inhibition, if not tolerance, it was not unexpected that the rejection of donor-type <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/skin-29065.html'>skin</a> grafts was not fully prevented. This might have been due to the small number of transferred CD8-bearing islet <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> as well as the presence of tissue-specific, i.e. <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/skin-29065.html'>skin</a> specific, allogeneic T cells. If skin-patches were modified themselves to express the CD8 α- chain, their rejection was prevented (unpublished observation).</p> <p>Tissue survival might have ultimately been supported by another immune inhibitory effect. We observed that the long term presence of the islet grafts expanded the activity of regulatory T cells. Liver <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> has been used for patients with liverbased metabolic disorder and end-stage liver failures. As alternative treatment, hepatocyte <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> has been investigated. This treatment’s theoretical advantages are severalfold. A less invasive operation is needed. The hepatocytes can be genetically manipulated <em>ex vivo</em> and can be cryopreserved. Cells from a single donor can be provided to several recipients. More than 150 clinical cases of hepatocyte <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> have been reported. The different trials have established immune rejection as a crucial hurdle to its success. A recent hepatocyte <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/transplantation-16150.html'>transplantation</a> of a patient with Crigler-Najjar suggested that CD8<sup>+</sup> T <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> were the primary driver of graft rejection. This observation could point to veto as the venue to facilitate hepatocyte acceptance. We therefore tested in mice whether hepatocytes transduced with AdCD8 would be accepted in allogeneic hosts. The <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> were harvested from Balb/c mice, transduced with AdCD8, and then injected into the spleens of C57Bl/6 mice. Similarly to allogeneic pancreatic islets, the hepatocytes survived this highly immune active environment. Since these studies were performed, we have optimized our Ad vector system and have moved to Ad vectors, whose genomes are fully deleted of all endogenous Ad genes [<a href="#18" title="18">18</a>-<a href="#20" title="20">20</a>]. These new vectors show little impact on the <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/physiology-2118.html'>physiology</a> of infected cells. Therefore, veto vectors based on this 4<sup>th</sup> generation Ad vector technology provide a unique opportunity to advance engineered veto into the clinic.</p> <h4>Conclusion</h4> <p>Classical veto has already found applications as the underpinning of a more broadly applicable CAR-T cell therapy and of more specific immune suppression for haploidentical HSC transplantations. Engineered veto will simplify and broaden its use to different cell and organ transplantations and possibly the treatment of certain autoimmune diseases. It may represent an avenue to induce immunological tolerance.</p> <h4>References</h4> <ol> <li id='Reference_Title_Link' value='1'><a name="1" id='1'></a>Fink PJ, Shimonkevitz RP, Bevan MJ. <a href="https://www.annualreviews.org/content/journals/10.1146/annurev.iy.06.040188.000555">Veto cells</a>. Annu Rev Immunol. 1988;6(1):115-137. <p>[<a href="https://doi.org/10.1146/annurev.iy.06.040188.000555">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=2849601618027418922&hl=en&as_sdt=0,5">Google Scholar</a>]</p> </li> <li id='Reference_Title_Link' value='2'><a name="2" id='2'></a>Ashby KM, Hogquist KA. <a href="https://www.nature.com/articles/s41577-023-00911-8">A guide to thymic selection of T cells</a>. Nat Rev Immunol. 2024;24(2):103-117. <p>[<a href="https://doi.org/10.1038/s41577-023-00911-8">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=16802611218717683120&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37464188/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='3'><a name="3" id='3'></a>Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. <a href="https://journals.physiology.org/doi/full/10.1152/advan.00066.2013">T cell responses: Naive to memory and everything in between</a>. Adv Physiol Educ. 2013;37(4):273-283. <p>[<a href="https://doi.org/10.1152/advan.00066.2013">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=15314009772623344959&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24292902/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='4'><a name="4" id='4'></a>Safinia N, Scotta C, Vaikunthanathan T, Lechler RI, Lombardi G. <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00438/full">Regulatory T cells: Serious contenders in the promise for immunological tolerance in transplantation</a>. Front Immunol. 2015;6:159309. <p>[<a href="https://doi.org/10.3389/fimmu.2015.00438">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=11835352023393474363&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26379673/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='5'><a name="5" id='5'></a>Chrobak P, Gress RE. <a href="https://www.sciencedirect.com/science/article/abs/pii/S000887490191771X?via%3Dihub">Veto activity of activated <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/bone-marrow-3619.html'>bone marrow</a> does not require perforin and fas ligand</a>. Cell Immunol. 2001;208(2):80-87. <p>[<a href="https://doi.org/10.1006/cimm.2001.1771">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=2131609791733373337&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11333140/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='6'><a name="6" id='6'></a>Hambor JE, Kaplan DR, Tykocinski ML. <a href="https://journals.aai.org/jimmunol/article-abstract/145/6/1646/23238/CD8-functions-as-an-inhibitory-ligand-in-mediating">CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8<sup>+</sup> cells</a>. J Immunol. 1990;145(6):1646-1652. <p>[<a href="https://doi.org/10.4049/jimmunol.145.6.1646">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=14204171338211107078&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1697305/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='7'><a name="7" id='7'></a>Hambor JE, Tykocinski ML, Kaplan DR. <a href="file:///C:\Users\U5T1582.DESKTOP-KB62ERU\AppData\Roaming\Microsoft\Word\Hambor%20JE,%20Tykocinski%20ML,%20Kaplan%20DR.%20Functional%20consequences%20of%20anti-sense%20RNA-mediated%20inhibition%20of%20CD8%20surface%20expression%20in%20a%20human%20T%20cell%20clone.%20The%20Journal%20of%20experimental%20medicine.%201988%20Oct%201;168(4):1237-45.">Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone</a>. J Exp Med. 1988;168(4):1237-1245. <p>[<a href="https://doi.org/10.1084/jem.168.4.1237">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=15489879217343317841&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2459296/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='8'><a name="8" id='8'></a>Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, Reisner Y. <a href="https://www.cell.com/immunity/fulltext/S1074-7613(00)00050-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761300000509%3Fshowall%3Dtrue">Anti-third party CD8+ CTLs as potent veto cells: Coexpression of CD8 and FasL is a prerequisite</a>. Immunity. 2000;13(4):507-515. <p>[<a href="https://doi.org/10.1016/S1074-7613(00)00050-9">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=5290834444810682558&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11070169/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='9'><a name="9" id='9'></a>Staerz UD, Kanagawa O, Bevan MJ. <a href="https://www.nature.com/articles/314628a0">Hybrid antibodies can target sites for attack by T cells</a>. Nature. 1985;314(6012):628-631. <p>[<a href="https://doi.org/10.1038/314628a0">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=13765671011615989718&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2859527/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='10'><a name="10" id='10'></a>Staerz UD, Bevan MJ. <a href="https://www.pnas.org/doi/abs/10.1073/pnas.83.5.1453">Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity</a>. Proc Natl Acad Sci U S A. 1986;83(5):1453-1457. <p>[<a href="https://doi.org/10.1073/pnas.83.5.1453">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=3463017470390988574&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2869486/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='11'><a name="11" id='11'></a>Abou Dalle I, Dulery R, Moukalled N, Ricard L, Stocker N, El-Cheikh J, et al. <a href="https://www.nature.com/articles/s41408-024-00989-w">Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: Current data and perspectives</a>. <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/blood-cancer-54183.html'>Blood Cancer</a> J. 2024;14(1):23. <p>[<a href="https://doi.org/10.1038/s41408-024-00989-w">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=10310233167078529315&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38272863/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='12'><a name="12" id='12'></a>Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1188049/full">From bench to bedside: The history and progress of CAR T cell therapy</a>. Front Immunol. 2023;14:1188049. <p>[<a href="https://doi.org/10.3389/fimmu.2023.1188049">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=3850091006473656608&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37256141/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='13'><a name="13" id='13'></a>Lonez C, Breman E. <a href="https://www.mdpi.com/2073-4409/13/2/146">Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?</a>. Cells. 2024;13(2):146. <p>[<a href="https://doi.org/10.3390/cells13020146">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=11104146238254294803&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38247837/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='14'><a name="14" id='14'></a>Reisner Y, Or-Geva N. <a href="https://www.sciencedirect.com/science/article/abs/pii/S0037196318301720?via%3Dihub">Veto <a target='_blank' href='https://www.longdom.org/peer-reviewed-journals/cells-53612.html'>cells</a> for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy</a>. Semin Hematol. 2019;56(3):173-182. <p>[<a href="https://doi.org/10.1053/j.seminhematol.2019.03.003">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=11093311483293569962&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31202427/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='15'><a name="15" id='15'></a>Qi Y, Berg R, Singleton MA, Debrick JE, Staerz UD. <a href="https://rupress.org/jem/article/183/5/1973/57695/Hybrid-antibody-mediated-veto-of-cytotoxic-T">Hybrid antibody mediated veto of cytotoxic T lymphocyte responses</a>. J Exp Med. 1996;183(5):1973-1980. <p>[<a href="https://doi.org/10.1084/jem.183.5.1973">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=4750294567087158009&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8642307/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='16'><a name="16" id='16'></a>Staerz UD, Lee DS, Qi Y. <a href="https://linkinghub.elsevier.com/retrieve/pii/S016756990001598X">Induction of specific immune tolerance with hybrid antibodies</a>. Immunol Today. 2000;21(4):172-176. <p>[<a href="https://doi.org/10.1016/S0167-5699(00)01598-X">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=13966964523270845740&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10740237/">PubMed</a>]</p> </li> <li id='Reference_Title_Link' value='17'><a name="17" id='17'></a>Qi Y, Zhang X, Cull JW, McCoy P, Cruz C, Dahl K, Staerz UD. <a href="https://www.biorxiv.org/content/10.1101/2024.01.05.574389v1.abstract">Protecting Allogeneic Pancreatic Islet Grafts by Engineered Veto</a>. bioRxiv. 2024. <p>[<a href="https://doi.org/10.1101/2024.01.05.574389">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=12858920495923565103&hl=en&as_sdt=0,5">Google Scholar</a>]</p> </li> <li id='Reference_Title_Link' value='18'><a name="18" id='18'></a>Brennan MB, Spiegel EK, Staerz UD, Wall C, Cull JW, Maslanik WJ, et al. <a href="https://patents.google.com/patent/US8871515B2/en">Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof</a>. United States Patent. 2014. </li> <li id='Reference_Title_Link' value='19'><a name="19" id='19'></a>Qi Y, Cull JW, Wall C, Maslanik W, Staerz UD<a href="https://www.biorxiv.org/content/10.1101/2024.04.04.588156v1.abstract">. The flexible, versatile and fast gregt platform of fully deleted helper-virus independent adenoviral vectors</a>. bioRxiv. 2024. <p>[<a href="https://doi.org/10.1101/2024.04.04.588156">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=11451269014815438425&hl=en&as_sdt=0,5">Google Scholar</a>]</p> </li> <li id='Reference_Title_Link' value='20'><a name="20" id='20'></a>Rammensee HG. <a href="https://www.tandfonline.com/doi/abs/10.3109/08830188909044780">Veto function <em>in vitro</em> and<em> in vivo</em></a>. Int Rev Immunol. 1989;4(2):175-1791. <p>[<a href="https://doi.org/10.3109/08830188909044780">Crossref</a>] [<a href="https://scholar.google.com/scholar?cluster=17868272330659771784&hl=en&as_sdt=0,5">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2485841/">PubMed</a>]</p> </li> </ol>   <div class="card bg-light mb-3"> <div class="card-body px-3 pb-0"> <h4 class="font-size-4"><a id="ai"></a>Author Info</h4> <a href='https://www.longdom.org/author/janae-w-cull-71344' title='Janae W Cull' style='color:#555; border-bottom:1px dotted #CCC;'>Janae W Cull</a>, <a href='https://www.longdom.org/author/yan-qi-71345' title='Yan Qi' style='color:#555; border-bottom:1px dotted #CCC;'>Yan Qi</a> and <a href='https://www.longdom.org/author/uwe-d-staerz-71346' title='Uwe D Staerz' style='color:#555; border-bottom:1px dotted #CCC;'>Uwe D Staerz</a><sup><a href='#Uwe_D_Staerz'>*</a></sup> <div> </div> Department of Research and Development, Greffex Inc, Colorado, USA<br> <div> </div> <p><strong>Citation:</strong> Staerz UD, Cull JW, Qi Y (2024) Veto-Engineering Immune Tolerance. J Hematol Thrombo Dis. 12:609.</p> <p> <strong>Received: </strong>14-Jun-2024, Manuscript No. JHTD-24-32036 (PQ); <strong>Editor assigned: </strong>17-Jun-2024, Pre QC No. JHTD-24-32036 (PQ); <strong>Reviewed: </strong>01-Jul-2024, QC No. JHTD-24-32036 (PQ); <strong>Revised: </strong>08-Jul-2024, Manuscript No. JHTD-24-32036 (PQ); <strong>Published:</strong> 15-Jul-2024 , DOI: 10.35248/2329-8790.24.12.609</p> <p><strong>Copyright: </strong>漏 2024 Staerz UD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p> </div> </div> </div> </div> </div> </section> <footer class="bg-blue-grey-900 py-3"> <div class="container"> <div class="row"> <div class="col-12 col-sm-4"> <h4 class="white font-size-4 fweight-400 border-bottom-1 pb-2">Content Links</h4> <ul class="list-unstyled footer-links font-size-3"> <li><a class="" href="https://www.longdom.org/online-tools.html" title="Click here">Tools</a> </li> <li><a class="" href="https://www.longdom.org/feedback.html" title="Click here">Feedback</a></li> <li><a class="" href="https://www.longdom.org/careers.html" title="Click here">Careers</a></li> <li><a class="" href="https://www.longdom.org/privacy-policy.html" title="Click here">Privacy Policy</a></li> <li><a class="" href="https://www.longdom.org/terms-conditions.html" title="Click here">Terms & Conditions</a></li> <li><a class="" href="https://www.longdom.org/authors-reviewers-editors.html" title="Click here">Authors, Reviewers & Editors</a></li> </ul> </div> <div class="col-12 col-sm-4"> <h4 class="white font-size-4 fweight-400 border-bottom-1 pb-2">Contact Longdom</h4> <p>Longdom Group SA<br> Avenue Roger Vandendriessche,<br> 18, 1150 Brussels, Belgium<br> Phone: +442038085340 <br><strong>Email:</strong> <a href="mailto:info@longdom.org" class="white" title="Click here">info@longdom.org</a></p> </div> <div class="col-12 col-sm-4"> <h4 class="white font-size-4 fweight-400 border-bottom-1 pb-2">Connect</h4> <nav class="nav nav-pills social-icons-footer flex-column a-pl-0"> <a href="https://www.facebook.com/longdompublisher" title="Click here" target="_blank" class="nav-link bg-facebook-hover"><i class="fab fa-facebook-f bg-facebook"></i> Facebook</a> <a href="https://www.linkedin.com/company/longdom-publishing-sl/" title="Click here" target="_blank" class="nav-link bg-linkedin-hover"><i class="fab fa-linkedin-in bg-linkedin"></i> Linkedin</a> <a href="https://twitter.com/LongdomP" title="Click here" target="_blank" class="nav-link bg-twitter-hover"><i class="fab fa-twitter bg-twitter"></i> Twitter</a> <a href="https://www.instagram.com/longdom_publisher/" title="Click here" target="_blank" class="nav-link bg-instagram-hover"><i class="fab fa-instagram bg-instagram"></i> Instagram</a> </nav> </div> </div> <div class="row text-center"> <div class="col"> <p>Copyright © 2025 <a href="https://www.longdom.org/" title="Click here" class="white">Longdom Publishing</a>.</p> </div> </div> </div> </footer>  <a href="#0" class="cd-top js-cd-top">Top</a>   <script defer src="https://code.jquery.com/jquery-3.3.1.min.js"></script> <script defer src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.7/umd/popper.min.js"></script> <script defer src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js"></script>  <script> jQuery(function($) { $(window).scroll(function fix_element() { $('#target').css( $(window).scrollTop() > 100 ? { 'position': 'fixed', 'top': '440px' } : { 'position': 'absolute', 'top': '440px' } ); return fix_element; }()); }); </script>   <script defer src="https://unpkg.com/feather-icons"></script> <script> feather.replace() </script>  <script defer src="/assets/js/scroll-to-top.js"></script>  <script defer type="text/javascript" src="/assets/js/coolautosuggest.js"></script> <script language="javascript" type="text/javascript"> $("#keyword").coolautosuggest({ url: "https://www.longdom.org/author-names.php?chars=", minChars: 3, }); </script> <script defer src="/assets/js/jquery.mCustomScrollbar.concat.min.js"></script> <script> // Scrollbar var Scrollbar = function() { "use strict"; // Handle Scrollbar Linear var handleScrollbarLinear = function() { $(".scrollbar").mCustomScrollbar({ theme: "minimal-dark" }); } return { init: function() { handleScrollbarLinear(); // initial setup for scrollbar linear } } }(); $(document).ready(function() { Scrollbar.init(); }); /*========================== Stikcy Navbar ============================*/ window.onscroll = function() { myFunction() }; var navbar = document.getElementById("sticky-navbar"); var sticky = navbar.offsetTop; function myFunction() { if (window.pageYOffset >= sticky) { navbar.classList.add("sticky") } else { navbar.classList.remove("sticky"); } } /*========================== Bootstrap Popover ============================*/ $(function () { $('[data-toggle="popover"]').popover() }) </script>  <script defer src="/assets/js/jquery.malihu.PageScroll2id.min.js"></script> <script> (function($){ $(window).on("load",function(){ $("a[rel='m_PageScroll2id']").mPageScroll2id(); }); })(jQuery); </script>  <script defer type="text/javascript" src="/assets/js/jquery.matchHeight-min.js"></script> <script> $(function() { $('.match-height').matchHeight({ byRow: true, property: 'height', target: null, }); }); </script> <script defer type="text/javascript" src="/assets/js/grids.min.js"></script> <script type="text/javascript"> // Equal Height var EqualHeight = function() { "use strict"; // Handle Equal Height var handleEqualHeight = function() { $(function($) { $('.equal-height').responsiveEqualHeightGrid(); }); } return { init: function() { handleEqualHeight(); // initial setup for equal height } } }(); $(document).ready(function() { EqualHeight.init(); }); </script>  <script defer src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-select/1.13.2/js/bootstrap-select.min.js"></script> <script> $('.selectpicker').selectpicker(); </script> <script> $(document).ready(function(){ var filecount = 1; $('.filerowclass').each(function(){ var countattr = $(this).attr('countattr'); if(filecount == countattr){ var countlink = $('#rowfile'+countattr+ ' .filelinkclass').length; if(countlink == 0){ $('#rowfile'+countattr).remove(); } } filecount++; }); }); </script>  <script type="text/javascript"> $(document).ready(function() { $("#wait").hide(); $("#jkeyword").keyup(function() { $("#wait").show(); //values of sending variables var jkeyword=$("#jkeyword").val(); var dataString = { 'jkeyword':jkeyword }; $.ajax ({ type: "POST", url: "https://www.longdom.org/journal-search.php", data: dataString, cache: false, success: function(html) { $("#jresult").html(html); $("#wait").hide(); } }); }); }); </script> <script type="text/javascript">function add_chatinline(){var hccid=52424552;var nt=document.createElement("script");nt.async=true;nt.src="https://mylivechat.com/chatinline.aspx?hccid="+hccid;var ct=document.getElementsByTagName("script")[0];ct.parentNode.insertBefore(nt,ct);} add_chatinline(); </script> <link href="https://cdn.jsdelivr.net/npm/select2@4.1.0-rc.0/dist/css/select2.min.css" rel="stylesheet" /> <script defer src="https://cdn.jsdelivr.net/npm/select2@4.1.0-rc.0/dist/js/select2.min.js"></script> </body> </html>